Licensavtal tar Astra Zeneca in i kampen om fetmapatienterna

Astra Zeneca ger sig nu på allvar in på det allt hetare fetmaområdet genom ett licensavtal med kinesiska Eccogene.

Nytt EU-godkännande för Astra Zenecas cancerbehandling Enhertu

Astra Zenecas läkemedel Enhertu har godkänts i EU som behandling för patienter med avancerad HER2-muterad icke-småcellig lungcancer (NSCLC).

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

Uncertainty about the government’s life science work

The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now question...

Tungt namn till Alzecure: ”Fantastiskt spännande"

Han har varit global forskningschef för jättebolagen Astra Zeneca och Eli Lilly – nu kliver profilen Jan Lundberg in i Alzecure Pharma.

Ready-to-install solutions for the lab-on-a-chip

Design for manufacturing lab-on-a-chip devices Reducing time-to-market together

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

The Swedish Foundation for Strategic Research

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

Astra Zeneca betalar över 10 miljarder för bolag inom sällsynta sjukdomar

Astra Zeneca köper Amolyt Pharma, som utvecklar läkemedel mot sällsynta endokrina sjukdomar. Prislappen ligger på upp till 1,05 miljarder dollar, motsvarande om...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

60% energibesparing med Wilden Pro-Flo Shift

Systemet är till och med 25–30% effektivare än de senaste och mest effektiva luftbesparingssystemen som finns på marknaden idag!

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

Conference recordings now available

Don't miss out on insights from leading experts.

Ny styrelseordförande för Lif

Astra Zenecas Nordenchef, Emelie Antoni, har valts in som ny styrelseordförande för Lif – de forskande läkemedelsföretagen.

Positiva resultat i ny cancerstudie med Imfinzi

Läkemedelsbolaget Astra Zenecas läkemedel Imfinzi (durvalumab), förbättrade signifikant den totala överlevnaden och progressionsfri överlevnad för patienter med...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”

For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the...

Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...